| ObjectiveTo observe the feasibility, safety and efficiency of the treatment of PercutaneousMicrowave Ablation Therapy(PMAT) combined with Recombinant Human Interleukin-2(rhIL-2) for metastatic liver cancer. To investigate the clinical application value of thetreatment.MethodsReference for the willingness of the patients and the size of the carcinoma nodule,seventy-two cases of hepatic metastasis carcinoma patients with gastrointestinal cancerwere randomly divided into two groups, Thirty-four patients in the observation group wereadministered PMAT and rhIL-2, The use of the rhIL-2：600.000U/time,3times one weekand for4weeks. The other38patients in the control group were only treated with PMAT,Two groups of patients in the age, sex, cancer nodules number and size, tumor source andthe Child-Pugh classification of liver function and others various aspects were nostatistically significant differences. The day before the operation and28days after theoperation, all of the patients were phlebotomized2ml blood in the condition of emptystomach in the morning， The T lymphocyte subgroups（CD3+、 CD4+、 CD8+、CD4+/CD8+）of the patients were measured by flow cytometry. The ablation effect,adverse reactions, quality of life, subjective symptom and T lymphocyte subsets of twogroups were observed and follow-up statistician the survival rate of half a year and1-yearandfor each group.ResultsAll of the patients endure the treatment, The immunologic function,the quality of life,and the subjective symptom were improved.1) The ablation effect: the CA rate of the72patients was92.04%（104/113）,and it was92.16%(47/51) in the observation group and 91.94%(57/62) in the control group. There is no statistically significant difference in thetwo groups. The CA rate of Diameter <3cm,3-5cm and>5cm cancer nodules also haveno statistically significant difference.2) tumor markers: Before the treatment, CEA positiverates were88.24%(30/34)and86.84%(33/38),AFP positive rates were20.59%（7/34）and23.68%（9/38）, in the observation group and control group respectively,There is nostatistically significant difference in the two groups. After the treatment, the CEA and AFPdecreased both of the two groups, the reduce of CEA was obvious(P<0.05).The declinerate and the negative rate of AFP in the observation groups were higher than that in controlgroup after the treatment, the difference was significant between groups(P<0.05).3) Thequality of life: After the treatment, the KPS, the diet and body weight growth rate for theobservation group and control group were58.82%(20/34)、55.88%(19/34)、44.18%(15/34)and31.58%(12/38)、36.84%(14/38)、36.84%(14/38）, respectively. The KPS of theobservation group were higher than that in control group（P<0.05）.4)The subjectivesymptom: After the treatment, the improve efficient of subjective symptom including liverpain, abdominal distension, hypodynamia and anorexia were much better in theobservation group than the control group.5) The immunologic function: The numbers of Tlymphocyte subgroups of the two groups had no obvious difference before the treatment.After the operation, The number of CD3+,CD4+and CD4+/CD8+ratio was increasedwhile CD8+was decreased both of the two groups. The rise of CD3+was obvious in theobservation group(P<0.05). The rise of CD4+, CD4+/CD8+ratio and the reduce of CD8+in the two groups had statistically significant difference after the treatment(P<0.05).Theratio of CD4+/CD8+in the observation groups were higher than that in control group, thedifference was significant between groups(P<0.05).6) The adverse reactions: The adversereactions of two groups were similar and the serious complications were not found. Theheating rate of the observation group（73.53%） was higher than that in the control group（44.74%）（P<0.05）.7)The recurrence rates:The0.5and1year recurrent rates for theobservation group and control group were11.76%（4/34）、32.35%（11/34）and31.58%（12/38）、60.53%（23/38）, respectively. The0.5and1year recurrence rates of theobservation group were higher than that in control group（P<0.05）.8)The survival rate: The0.5and1year survival rates for the observation group and control group were91.18%(31/34)、70.59%(24/34) and89.47%(34/38)、47.37%(18/38),respectively. The1year survival rates of the observation group was higher than that in control group（P<0.05）. ConclusionsThe PMAT combined with rhIL-2is an effective and safe method to treat hepaticmetastasis carcinoma. It can improve the quality of life and the systemic anti-tumorimmunity of the patients, and increase survival periods and reduce recurrence rate inpatients with liver carcinoma. |
PDF Full Text Request